283 related articles for article (PubMed ID: 27443528)
1. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sterzyſska K; Sosiſska P; Andrzejewska M; Zawierucha P; Nowicki M; Zabel M
Int J Biochem Cell Biol; 2016 Sep; 78():248-259. PubMed ID: 27443528
[TBL] [Abstract][Full Text] [Related]
2. Effect of
Nowacka M; Ginter-Matuszewska B; Świerczewska M; Sterzyńska K; Nowicki M; Januchowski R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328460
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.
Croker AK; Allan AL
Breast Cancer Res Treat; 2012 May; 133(1):75-87. PubMed ID: 21818590
[TBL] [Abstract][Full Text] [Related]
4. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling.
Kim D; Choi BH; Ryoo IG; Kwak MK
Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520
[TBL] [Abstract][Full Text] [Related]
5. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
[TBL] [Abstract][Full Text] [Related]
6. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance.
Moreb JS; Ucar D; Han S; Amory JK; Goldstein AS; Ostmark B; Chang LJ
Chem Biol Interact; 2012 Jan; 195(1):52-60. PubMed ID: 22079344
[TBL] [Abstract][Full Text] [Related]
7. [The mechanism of topotecan resistance in ovarian cancer cell line].
Jia P; Wu SB; Li F; Xu Q; Wu MF; Liao GN; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):139-42. PubMed ID: 15196431
[TBL] [Abstract][Full Text] [Related]
8. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
Yao W; Wang L; Huang H; Li X; Wang P; Mi K; Cheng J; Liu H; Gu C; Huang L; Huang J
BMC Cancer; 2020 Apr; 20(1):315. PubMed ID: 32293355
[TBL] [Abstract][Full Text] [Related]
9. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Nowacka M; Kaźmierczak D; Andrzejewska M; Rusek D; Brązert M; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583585
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
11. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sujka-Kordowska P; Andrzejewska M; Zabel M
Biomed Res Int; 2013; 2013():241763. PubMed ID: 23484165
[TBL] [Abstract][Full Text] [Related]
12. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
[TBL] [Abstract][Full Text] [Related]
13. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.
Jia P; Wu S; Li F; Xu Q; Wu M; Chen G; Liao G; Wang S; Zhou J; Lu Y; Ma D
Int J Gynecol Cancer; 2005; 15(6):1042-8. PubMed ID: 16343180
[TBL] [Abstract][Full Text] [Related]
16. PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
Świerczewska M; Sterzyńska K; Wojtowicz K; Kaźmierczak D; Iżycki D; Nowicki M; Zabel M; Januchowski R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027318
[No Abstract] [Full Text] [Related]
17. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
[TBL] [Abstract][Full Text] [Related]
19. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
[TBL] [Abstract][Full Text] [Related]
20. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
